TD Asset Management’s Stoke Therapeutics STOK Stock Holding History

TD Asset Management’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.2M	Sell	67,200 -7,200	-10%	-$231K	﹤0.01%	953
2026 Q1	$2.42M	Buy	+74,400	New	+$2.44M	﹤0.01%	925
2023 Q3	–	Sell	-26,186	Closed	-$278K	–	1448
2023 Q2	$278K	Hold	26,186	–	–	﹤0.01%	1347
2023 Q1	$218K	Hold	26,186	–	–	﹤0.01%	1373
2022 Q4	$242K	Hold	26,186	–	–	﹤0.01%	1376
2022 Q3	$341K	Sell	26,186 -8,528	-25%	-$136K	﹤0.01%	1353
2022 Q2	$459K	Hold	34,714	–	–	﹤0.01%	1302
2022 Q1	$731K	Hold	34,714	–	–	﹤0.01%	1288
2021 Q4	$833K	Buy	34,714 +5,600	+19%	+$134K	﹤0.01%	1307
2021 Q3	$741K	Hold	29,114	–	–	﹤0.01%	1319
2021 Q2	$834K	Sell	29,114 -7,900	-21%	-$279K	﹤0.01%	1295
2021 Q1	$1.44M	Buy	37,014 +5,673	+18%	+$323K	﹤0.01%	1182
2020 Q4	$1.94M	Buy	31,341 +9,062	+41%	+$415K	﹤0.01%	1046
2020 Q3	$746K	Hold	22,279	–	–	﹤0.01%	1144
2020 Q2	$531K	Hold	22,279	–	–	﹤0.01%	1197
2020 Q1	$510K	Buy	22,279 +2,400	+12%	+$59.3K	﹤0.01%	1167
2019 Q4	$563K	Hold	19,879	–	–	﹤0.01%	1225
2019 Q3	$427K	Buy	+19,879	New	+$554K	﹤0.01%	1199

Other funds holding STOK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TD Asset Management's STOK Position: Q2 2026 in Review

TD Asset Management reduced its Stoke Therapeutics (STOK) stake by 9.7% in Q2 2026, selling an estimated $231K and leaving 67,200 shares worth $2.2M. The position accounts for ﹤0.01% of the portfolio, ranked #953.

TD Asset Management first reported a position in STOK in Q3 2019 and has held it in 18 quarters since. The position peaked at $2.42M in Q1 2026. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

TD Asset Management held 67,200 shares of Stoke Therapeutics worth $2.2M as of Q2 2026.
TD Asset Management sold 7,200 Stoke Therapeutics shares in Q2 2026, an estimated $231K.
Stoke Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #953 holding.
TD Asset Management first reported a position in Stoke Therapeutics in Q3 2019 and has held it in 18 quarters since.
TD Asset Management's Stoke Therapeutics position peaked at $2.42M in Q1 2026.
197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.